



January Formulary Update

Effective January 26, 2026

New Formulary Medications

- a. chloroprocaine (CLOROTEKAL) parenteral injection
- b. phenazopyridine (PYRIDIUM) oral solid (previously discontinued)

New Formulary Restricted Medications

- a. BC Cancer: addition of following medications restricted to the indications outlined in the BC Cancer Benefit Drug List
 - avapritinib (AYVAKYT) oral tablets
 - momelotinib (OJJAARA) oral tablets
 - pemigatinib (PEMAZYRE) oral tablets
 - zolbetuximab (VYLOY) parenteral injection
- b. tocilizumab (TYENNE) parenteral injection: restricted to the prophylaxis of cytokine release syndrome (CRS) associated with bispecific T-cell engager (BiTE) therapy OR treatment of CRS from BiTE therapy or chimeric antigen receptor (CAR) T-cell therapy

Excluded Medications

- a. tocilizumab (ACTEMRA) parenteral injection

Discontinued Medications

- a. dipyridamole-ASA (AGGRENOX) extended release oral capsules
- b. leuprolide (LUPRON) injection

January 26, 2026 For the information of physicians, nurses, and pharmacists. PLEASE POST	Formulary Changes	✓	For further information contact: <i>Jessica Granberg</i> Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Medication Change		